Synaptogenix, Inc is a biopharmaceutical company focused on developing drug candidates, such as Bryostatin-1, for treating Alzheimer's disease. They're also exploring the therapeutic applications of Bryostatin in other cognitive diseases and dysfunctions. Based in New York, the company has licensing agreements with Stanford University and other institutions.